Skip to main content Accessibility help
×
Home

Safety of Palivizumab Stewardship in Conjunction with Infection Prevention and Control Strategies for Healthcare-Associated Respiratory Syncytial Virus Infections

  • Rupal M. Patel (a1), Larry K. Kociolek (a2) (a3), Emily Merrick (a2), Caroline Reuter (a2), Kenny Kronforst (a2) (a4), Xiaotian Zheng (a5) (a6) and Sameer J. Patel (a2) (a3)...

Abstract

Transitioning from administration of monthly palivizumab to a single dose at discharge was associated with substantial pharmacy cost savings. With the concurrent adoption of private hospital rooms and visitor restriction policies, hospital-wide and neonatal intensive care unit healthcare-associated respiratory syncytial virus infections decreased following these changes.

Infect Control Hosp Epidemiol 2018;39:485–487

Copyright

Corresponding author

Address correspondence to Rupal Patel, PharmD, 1000 Blythe Blvd, Charlotte, NC, 28203 (rupal.patel@carolinashealthcare.org).

References

Hide All
1. Jain, S, Williams, DJ, Arnold, SR, et al. Community-acquired pneumonia requiring hospitalization among US children. N Engl J Med 2015;372:835845.
2. Stockman, LJ, Curns, AT, Anderson, LJ, Fischer-Langley, G. Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997-2006. Pediatr Infect Dis J 2012;31:59.
3. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics 1998;102:531537.
4. American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics 2003;112:14421446.
5. Vendetti, N, Gerber, JS, Sammons, JS, Fisher, BT, Zaoutis, TE, Coffin, SE. Administration of palivizumab in the NICU. Hosp Pediatr 2016;6:354358.
6. Committee on Infectious Diseases. From the American Academy of Pediatrics: Policy statements—modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics 2009;124:16941701.
7. American Academy of Pediatrics Committee on Infectious Diseases, American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics 2014;134:415420.
8. Zembles, TN, Gaertner, KM, Gutzeit, MF, Willoughby, RE. Implementation of American Academy of Pediatrics guidelines for palivizumab prophylaxis in a pediatric hospital. Am J Health Syst Pharm 2016;73:405408.
9. Ohler, KH, Pham, JT. Comparison of the timing of initial prophylactic palivizumab dosing on hospitalization of neonates for respiratory syncytial virus. Am J Health Syst Pharm 2013;70:13421346.

Safety of Palivizumab Stewardship in Conjunction with Infection Prevention and Control Strategies for Healthcare-Associated Respiratory Syncytial Virus Infections

  • Rupal M. Patel (a1), Larry K. Kociolek (a2) (a3), Emily Merrick (a2), Caroline Reuter (a2), Kenny Kronforst (a2) (a4), Xiaotian Zheng (a5) (a6) and Sameer J. Patel (a2) (a3)...

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed